{"id":"90160d73-e9ef-5416-a527-d9782b95e283","stable_key":"c94a9824-35fb-523c-b421-dc7341218dcb:indicaxanthin-cisplatin-low-dose","predicate":"potentiates_cisplatin_reduction","statement":"Low-micromolar indicaxanthin enhanced the cisplatin-associated loss of HeLa-cell viability in a separate concentration-response experiment.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"0db286b3-e596-5c6d-944a-f749c6ef3939","mechanism_event_label":"Low-micromolar indicaxanthin enhanced the cisplatin-associated loss of HeLa-cell viability in a separate concentration-response experiment.","subject":{"id":"f2a6e469-05f0-5596-9054-da926389f584","slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"},"object":{"id":"a654a704-328f-580a-b8da-2602c433dbeb","slug":"human-hela-viability","display_name":"Viability of human HeLa cervical cancer cells","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0db286b3-e596-5c6d-944a-f749c6ef3939","stable_key":"c94a9824-35fb-523c-b421-dc7341218dcb:indicaxanthin-cisplatin-low-dose-event","event_type":"observed_relationship","label":"Low-micromolar indicaxanthin enhanced the cisplatin-associated loss of HeLa-cell viability in a separate concentration-response experiment.","description":"Low-micromolar indicaxanthin enhanced the cisplatin-associated loss of HeLa-cell viability in a separate concentration-response experiment.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"f2a6e469-05f0-5596-9054-da926389f584","slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"a654a704-328f-580a-b8da-2602c433dbeb","slug":"human-hela-viability","display_name":"Viability of human HeLa cervical cancer cells","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"bdb83796-78cf-5b54-9ca6-4dab19b33600","slug":"cisplatin","display_name":"Cisplatin","entity_type_key":"drug"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Indicaxanthin 2, 5 or 10 micromolar plus a cisplatin concentration series","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"24 h","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary open full text, relevant results/methods and PubMed metadata.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human HeLa cervical cancer cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Lower indicaxanthin concentrations were examined in a separate viability experiment; do not transfer all high-dose mechanistic measurements to this range.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Dedicated indicaxanthin chapter; original betalain family identity and shared claims preserved.","comparator":null,"unit":null,"notes":"","entity":{"slug":"indicaxanthin","display_name":"Indicaxanthin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human HeLa cervical cancer cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Low-micromolar indicaxanthin enhanced the cisplatin-associated loss of HeLa-cell viability in a separate concentration-response experiment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. (2020). https://pubmed.ncbi.nlm.nih.gov/32630700/ DOI: 10.3390/biom10070994","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vitro co-treatment","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Viability assay","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"4605775b-423d-5fb9-b82f-66fe661edd3d","evidence_kind":"source_excerpt","locator":"Lines 316-325","start_line":316,"end_line":325,"excerpt":"## indicaxanthin-cisplatin-low-dose\nLow-micromolar indicaxanthin enhanced the cisplatin-associated loss of HeLa-cell viability in a separate concentration-response experiment.\nModel/species: Human HeLa cervical cancer cells\nTissue: Viability assay\nExposure: Indicaxanthin 2, 5 or 10 micromolar plus a cisplatin concentration series\nRoute: In vitro co-treatment\nDuration: 24 h\nLimits: Lower indicaxanthin concentrations were examined in a separate viability experiment; do not transfer all high-dose mechanistic measurements to this range.\nPrimary reference: The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. (2020). https://pubmed.ncbi.nlm.nih.gov/32630700/ DOI: 10.3390/biom10070994\nAccess: Primary open full text, relevant results/methods and PubMed metadata.","model_system":"Human HeLa cervical cancer cells","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact archived curation span; original paraphrase with primary citation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"18b7303c-98b7-54cb-ae8e-a8c6257657b1","stable_key":"import-c94a9824-35fb-523c-b421-dc7341218dcb","title":"Indicaxanthin: mechanisms, molecular forms and cross-actor connections (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted curation of thirteen additional primary studies, with twenty-six existing claims from eight studies linked unchanged. Study-specific citations and limitations retained. Not publisher full text.","file_path":"","sha256":"fd5e7b3a108073af5a8cad0e226a483ae2cda3b0e1daed387553ee441acecd5f","revision_id":"f3357c22-1be7-5502-b4f5-415d19c3cf5a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}